Ptc Therapeutics Q3 2026 earnings

PTCT · 2026-10-29 16:10 AMC ET · 8-K on SEC · 10-Q on SEC

Record product revenue and raised full-year guidance driven by Sephience, offset by a net loss due to an acquired R&D asset.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$357.8M+69.5%-0.8%Ex. 99.1, income statement
EPS (GAAP)-$0.62-410%-$1.54Ex. 99.1, income statement
EPS (adjusted)-$0.45-N/A-$1.37Ex. 99.1, income statement
Net income-$51.7M-N/A-$135.2MEx. 99.1, income statement
Adj. EBITDA-$13.8M-N/A-$30.8MEx. 99.1, income statement
Adj. EBITDA margin-3.9%-N/A-8.7 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Net product revenue$275.9M+110.8%77.1%Sephience led growth
Royalty revenue$81.7M+15.3%22.8%—
Collaboration and license revenue$0.2M-97.8%0.1%—

Margins and costs

  • Gross margin N/A
  • Operating expenses $332.7M (+59.9% YoY)
  • One-offs in the quarter Acquired in-process R&D expense: $111.0M; Loss on extinguishment of debt: $19.3M
  • Effective tax rate -25.6% (prior-year -38.9%, year-to-date -46.3%)
  • Non-GAAP bridge Adds back stock-based compensation to R&D and SG&A; excludes acquired in-process R&D and debt extinguishment.

KPIs

MetricActualPrior quarterPrior yearChange
Cash$2.13B$2.23B$1.95B-$103M
Total debt$536.3M$591.0M$286.6M-$55M

Guidance

MetricGuidePrior guideChange
Total revenue$1.29B - $1.32B$1.18B - $1.28B+$110M - $40M
Product revenue$960M - $990M$850M - $950M+$110M - $40M
GAAP R&D expense$335M - $345M$325M - $335M+$10M - $10M
GAAP SG&A expense$345M - $355M$335M - $345M+$10M - $10M

What drove it

  • Revenue story Net product revenue grew 110.8% YoY to $275.9M, driven by Sephience; Royalty revenue grew 15.3% YoY to $81.7M; Collaboration and license revenue dropped 97.8% YoY to $0.2M.
  • EPS story GAAP net loss widened to -$0.62 per share due to an $111.0M acquired in-process R&D charge and a $19.3M debt extinguishment loss.
  • One-off check Acquired in-process R&D expense: $111.0M; Loss on extinguishment of debt: $19.3M.

The good

  • Record Q3 product revenue of $275.9M
  • Raised full-year product revenue guidance to $960M-$990M

The bad

  • Net loss of $51.7M due to one-time charges
  • Adj. EBITDA margin turned negative at -3.9%

The ugly

  • none

Open questions

  • What caused the 97.8% drop in Collaboration and license revenue?
  • What is the specific impact of the ST-920 acquisition on future R&D expense?
Full release

Earnings: PTCT — filed 2026-10-29

Ptc Therapeutics, Inc. (PTCT) · Form 8-K, Item 2.02 · Filed · SEC filing

​

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

​ – Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – ​ – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – ​ – Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in the US and ongoing global expansion – ​ – Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 – ​

WARREN, N.J., October 29, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2026.

​

"We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year," said Matthew B. Klein, M.D., Chief Executive Officer. "Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”

​

Key Corporate Updates

​

Third Quarter 2026 Financial Highlights

​

PTC Updates Full-Year 2026 Financial Guidance

​

Non-GAAP Financial Measures

In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.

​

​

PTC Therapeutics, Inc.

Consolidated Statements of Operations

(in thousands, except share and per share data)

​

* In Q3 2026, the Company purchased the ST-920 asset from Sangamo Therapeutics, Inc. and paid an upfront cash consideration of $111.0 million which was recorded as Acquired in-process research and development expense.

​

PTC Therapeutics, Inc.

Summary Consolidated Balance Sheets

(in thousands, except share data)

​

​

PTC Therapeutics, Inc.

Reconciliation of GAAP to Non-GAAP Projected Full Year 2026 R&D and SG&A Expense

(in millions)

​

​

Acronyms

AAV: adeno-associated virus

BLA: Biologics License Application

CHF: Confoederatio Helvetica Francs (Swiss francs)

DHODH: dihydroorotate dehydrogenase

FA: Friedreich’s ataxia

FDA: US Food and Drug Administration

GAAP: Generally Accepted Accounting Principles

HD: Huntington’s disease

MSH3: MutS Homolog 3 (human gene)

NDA: New Drug Application

NLRP3: NOD-, LRR- and pyrin domain-containing 3 (multi-protein complex)

R&D: Research and Development

SG&A: Selling, General, and Administrative

​

Today's Conference Call and Webcast Reminder

To access the live webcast, please visit the “Events & Presentations” page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.

​

About PTC Therapeutics, Inc.

PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on LinkedIn, X, Facebook and Instagram.

​

For more information please contact:

​

Investors:

Ellen Cavaleri

+1 (615) 618-6228 ecavaleri@ptcbio.com

​

Media:

Jeanine Clemente

+1 (908) 912-9406 jclemente@ptcbio.com

​

Financial statements

Income Statement

Three Months Ended September 30, — (in thousands, except share and per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues:
Net product revenue275,894130,956740,286402,711
Collaboration and license revenue2299,25850,967998,430
Royalty revenue81,68470,793199,624164,837
Total revenues357,807211,007990,8771,565,978
Operating expenses:
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets23,66415,78171,61340,063
Amortization of acquired intangible assets12,5957,53436,01715,393
Research and development (1)105,353100,158305,376322,121
Selling, general and administrative (2)80,08184,046246,894250,269
Change in the fair value of contingent consideration-800
Tangible asset impairment and losses on transactions, net472927648
Acquired in-process research and development *111,000111,000
Total operating expenses332,693207,991771,827627,694
Income from operations25,1143,016219,050938,284
Interest expense, net-45,866-32,592-143,377-97,042
Other (expense) income, net-1,0736,502-2,415-5,540
Loss on extinguishment of debt-19,263-19,263
(Loss) income before income tax (expense) benefit-41,088-23,07453,995835,702
Income tax (expense) benefit-10,60538,970-25,001-18,093
Net (loss) income attributable to common stockholders-51,69315,89628,994817,609
Weighted-average shares outstanding:
Basic (in shares)83,476,10078,471,11983,004,62578,642,478
Diluted (in shares)83,476,10087,115,36992,253,67586,899,727
Net (loss) income per share—basic (in dollars per share)-0.620.20.3510.4
Net (loss) income per share—diluted (in dollars per share)-0.620.20.349.45
(1) Research and development reconciliation
GAAP research and development105,353100,158305,376322,121
Less: share-based compensation expense10,4799,13332,15526,827
Non-GAAP research and development94,87491,025273,221295,294
(2) Selling, general and administrative reconciliation
GAAP selling, general and administrative80,08184,046246,894250,269
Less: share-based compensation expense13,34810,29338,38429,202
Non-GAAP selling, general and administrative66,73373,753208,510221,067

Balance Sheet

September 30, 2026 — (in thousands, except share data)

September 30, 2026December 31, 2025
Cash, cash equivalents and marketable securities2,127,9181,945,371
Total Assets3,207,7152,898,767
Total debt536,268286,631
Total deferred revenue1,9752,040
Total liability for sale of future royalties2,305,6032,308,366
Total liabilities3,398,9243,104,080
Total stockholders' deficit (83,535,767 and 81,474,366 common shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively)-191,209-205,313
Total liabilities and stockholders' deficit3,207,7152,898,767

Cash Flow

From the 10-Q · Nine Months Ended September 30, — In thousands

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities
Net income28,994817,609
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization48,10425,913
Non-cash operating lease expense5,3585,635
Non-cash royalty revenue related to sale of future royalties-199,624-149,160
Non-cash interest expense on liability related to sale of future royalties196,861149,305
Change in valuation of contingent consideration-800

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading “PTC Updates Full-Year 2026 Financial Guidance”, including with respect to (i) 2026 total product revenue guidance and total revenue guidance and (ii) 2026 GAAP and non-GAAP R&D and SG&A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, meetings with regulatory agencies, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance," "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," "aim," and similar expressions.

​... (truncated)ents could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including commercialization and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in geographies in which it has been approved and the effect of the European Commission's adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna and the withdrawal of the Translarna NDA in the US on other regulatory bodies; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; expectations with respect to ST-920, including the expected timing of regulatory submissions and potential approvals, and the potential achievement of regulatory milestones and contingent payments PTC may be obligated to make; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including with respect to the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses and potential approvals and other matters; expectations with respect to the commercialization of Evrysdi under PTC's SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; expectations regarding PTC's product candidates, including the timing of clinical trials and studies; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

​

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience, Translarna, Emflaza, Upstaza, Kebilidi, Evrysdi, Tegsedi or Waylivra.

​

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.